AIM
RCUS icon

Aigen Investment Management’s Arcus Biosciences RCUS Stock Holding History

Aigen Investment Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-12,516
Closed -$215K – 999
2020
Q3 		$215K Buy
+12,516
New +$280K 0.03% 623

Other funds holding RCUS

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aigen Investment Management's RCUS Position: Q4 2020 in Review

Aigen Investment Management sold out of Arcus Biosciences (RCUS) in Q4 2020, closing a stake of 12,516 shares — an estimated $215K sold.

Aigen Investment Management first reported a position in RCUS in Q3 2020 and held it in 1 quarter. The position peaked at $215K in Q3 2020. 148 funds tracked by Wall St. Rank hold RCUS as of Q4 2020.

  • Aigen Investment Management reported no remaining Arcus Biosciences position as of Q4 2020 after selling out during the quarter.
  • Aigen Investment Management sold 12,516 Arcus Biosciences shares in Q4 2020, an estimated $215K.
  • Aigen Investment Management first reported a position in Arcus Biosciences in Q3 2020 and held it in 1 quarter.
  • Aigen Investment Management's Arcus Biosciences position peaked at $215K in Q3 2020.
  • 148 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2020.

Based on Aigen Investment Management's 13F filing for Q4 2020, filed 12 Feb 2021.